- 
                        CINV Drugs Market to Reach USD 2.49 Bn by 2032 | Key Trends, Pipeline Therapies & Leading Players (2025–2032)
                        20 Oct 2025 08:20 GMT
                        
                           … lucrative CINV pipeline drug opportunities for pharmaceutical companies worldwide.
                          
                           … enter late-stage clinical trials by 2026.
                          
                          Helsinn …  nausea and vomiting treatment and expand supportive  … market-report/cancer-vaccines-drug-pipeline-market/218875 …
                         
- 
                        Nanocrystalline Drug Delivery Systems for Natural Compounds: Progress, Challenges and Future Opportunities
                        17 Sep 2025 17:46 GMT
                        
                           … remedies in the realm of drug development.6
                          Despite their considerable medicinal … products: a review. Biotechnol Adv. 2015;33( …  for the treatment of bronchopulmonary aspergillosis.  …  polysaccharide nanocrystals as pharmaceutical excipients. Carbohydr Polym.  …
                         
- 
                        $19.5M Plan Pitched For Drug Rehab Revival
                        18 Jul 2025 20:36 GMT
                        
                           …  2026?
                          • Will Medicaid be accepted for all services?
                          • Does Emend have any …  with Emend, as implied by Emend’s CON application?
                          • Will Emend provide treatment for … ; Deeper Financial Chaos Revealed
                          • 2nd Drug Rehab Exec Dies; Employees, Patients …
                         
- 
                        Advances in veterinary oncology: From a melanoma vaccine to genetic testing
                        15 Mar 2025 02:45 GMT
                        
                           …  that.”
                          Much like the human medication Emend, an NK1 receptor antagonist for … . As Bergman explained, the FDA-approved drug has been found to successfully … , and prior to the melanoma vaccine, treatment options were limited, with many …
                         
- 
                        Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
                        17 Sep 2024 10:00 GMT
                         … side effects of chemotherapy medications which can affect  … Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Camurus AB, … nausea drugs. For example, doctors can use Merck's Emend  … induced nausea and vomiting treatment market, presenting historical data … 
- 
                        25 drugs at Mark Cuban's online pharmacy with biggest cost reductions
                        06 Apr 2024 00:30 GMT
                        
                           … Drugs now sells hundreds of generics and about 20 branded medications … pharmacy benefit managers. 
                          Each drug is priced at its  … medications with the biggest price cuts sold at Cost Plus Drugs … 315.80
                          Aprepitant (generic for Emend)
                          Retail price: $2,691 …
                         
- 
                        Human medicines European public assessment report (EPAR): Emend, aprepitant, Date of authorisation: 11/11/2003, Revision: 31, Status: Authorised
                        08 Mar 2024 16:26 GMT
                         … They compared the effectiveness of Emend, taken in combination with  …  studies showed that adding Emend to the standard combination was … no need for any other medication to control nausea and  …  children given ondansetron alone. Emend was also effective in the … 
- 
                        Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Down 15.8% in September
                        14 Oct 2023 16:29 GMT
                         … subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous  … ' ratings for Ono Pharmaceutical and related companies with MarketBeat … 
- 
                        Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
                        13 Sep 2023 02:34 GMT
                        
                           … Sharp & Dohme Corp.
                          Emend (aprepitant) capsules
                          11… not paid
                          Bayer Healthcare Pharmaceuticals, Inc.
                          Eovist ( … /14)
                          The Medicines Company
                          Cleviprex (clevidipine)  …  US, Inc. (formerly Luitpold Pharmaceuticals, Inc.)
                          Sprix (ketorolac tromethamine …
                         
- 
                        Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Significant Drop in Short Interest
                        14 Sep 2023 19:10 GMT
                         … subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It … Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous  … ' ratings for Ono Pharmaceutical and related companies with MarketBeat …